Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 12/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527515 | 0.96 | CACNA1B (0.68) | CACNA1B | |
| SCHEMBL7532654 | 0.91 | CACNA1B (0.63) | CACNA1B | |
| SCHEMBL7531855 | 0.91 | CACNA1B (0.63) | CACNA1B | |
| SCHEMBL5855026 | 0.90 | CACNA1B (0.70) | CACNA1B | |
| SCHEMBL7526220 | 0.89 | CACNA1B (0.81) | CACNA1B | |
| SCHEMBL5855031 | 0.85 | CACNA1B (0.63) | CACNA1B | |
| SCHEMBL7532449 | 0.85 | CACNA1B (1.00) | CACNA1B | |
| SCHEMBL7656396 | 0.83 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL27541926 | 0.82 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL7524826 | 0.81 | CACNA1B (0.59) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.